Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Mallory, Raburn M ^a   Malkin, Elissa ^a   Ambrose, Christopher S ^a   Bellamy, Terramika ^a   Shi, Li ^a   Yi, Tingting ^a   Jones, Taff ^a   Kemble, George ^a   Dubovsky, Filip ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO;

ACTIVE IMMUNIZATION; ADOLESCENT; ADULT; ANTIBODY TITER; APPETITE; ARTICLE; CELLULITIS; CHILD; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GALLBLADDER DISEASE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNITY; HYPOTHYROIDISM; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NOSE CONGESTION; OSTEOMYELITIS; PHYSICAL ACTIVITY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; RISK ASSESSMENT; SCHOOL CHILD; SEROCONVERSION; SEROLOGY; SIDE EFFECT; SNEEZING; SORE THROAT; VOMITING; IMMUNOLOGY; INFLUENZA; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; VIROLOGY;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PLACEBOS; YOUNG ADULT;

EID: 78149426225     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013755     Document Type: Article

References (38)

1. Maassab HF (1969) Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 102: 728-732.
2. Jin H, Lu B, Zhou H, Ma C, Zhao J, et al. (2003) Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306: 18-24.
3. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM (2004) Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 3: 643-654.
4. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM (2005) A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 115: 1039-1047.
5. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, et al. (2006) Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 194: 1032-1039.
6. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1343-1351.
7. Jackson LA, Neuzil KM, Baggs J, Davis RL, Black S, et al. (2006) Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study. Pediatrics 118: 2032-2037.
8. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, et al. (1999) Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282: 137-144.
9. Halloran ME, Longini IM, Jr., Gaglani MJ, Piedra PA, Chu H, et al. (2003) Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 158: 305-311.
10. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, et al. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356: 685-696.
11. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, et al. (2000) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136: 168-175.
12. Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, et al. (2005) Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116: e397-407.
13. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, et al. (2007) Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 120: e553-564.
14. World Health Organization (2008) Business plan for the global pandemic influenza action plan to increase vaccine supply. Available: http://www.who.int/entity/vaccine_research/documents/Report%20McKinsey%2 0Business% 20Plan%20Flu3.pdf. Accessed April 19, 2010.
15. King JC, Jr., Stoddard JJ, Gaglani MJ, Moore KA, Magder L, et al. (2006) Effectiveness of school-based influenza vaccination. N Engl J Med 355: 2523-2532.
16. Carpenter LR, Lott J, Lawson BM, Hall S, Craig AS, et al. (2007) Mass distribution of free, intranasally administered influenza vaccine in a public school system. Pediatrics 120: e172-178.
17. Hull HF, Frauendienst RS, Gundersen ML, Monsen SM, Fishbein DB (2008) School-based influenza immunization. Vaccine 26: 4312-4313.
18. Chen Z, Wang W, Zhou H, Suguitan AL, Jr., Shambaugh C, et al. (2010) Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 84: 44-51.
19. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, et al. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37: 937-943.
20. Chan IS, Zhang Z (1999) Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 55: 1202-1209.
21. Centers for Disease Control and Prevention (2009) Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep 58: 1100-1101.
22. Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, et al. (2007) Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26: 619-628.
23. Zangwill KM, Belshe RB (2004) Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 23: 189-197.
24. Breiman RF, Brooks WA, Goswami D, Lagos R, Borja-Tabora C, et al. (2009) A multinational, randomized, placebo-controlled trial to assess the immunogenic-ity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 27: 5472-5479.
25. Bracco H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, et al. (2009) Efficacy and safety of one and two doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J. pp 365-371.
26. Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, et al. (2010) Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 28: 1566-1574.
27. Maassab HF, Francis T, Jr., Davenport FM, Hennessy AV, Minuse E, et al. (1969) Laboratory and clinical characteristics of attenuated strains of influenza virus. Bull World Health Organ 41: 589-594.
28. Centers for Disease Control and Prevention (2009) Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 58: 1351-1356.
29. Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, et al. (2008) Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 26: 4940-4946.
30. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, et al. (2008) Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 15: 1042-1053.
31. Lee MS, Mahmood K, Adhikary L, August MJ, Cordova J, et al. (2004) Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 23: 852-856.
32. King JC, Jr., Lagos R, Bernstein DI, Piedra PA, Kotloff K, et al. (1998) Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 177: 1394-1397.
33. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, et al. (1998) The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338: 1405-1412.
34. Zangwill KM, Droge J, Mendelman P, Marcy SM, Partridge S, et al. (2001) Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 20: 740-746.
35. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, et al. (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18: 899-906.
36. Edwards KM, Dupont WD, Westrich MK, Plummer WD, Jr., Palmer PS, et al. (1994) A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169: 68-76.
37. Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, et al. (2009) Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 27: 1101-1110.
38. Piedra P (2010) Preliminary Information on the Effectiveness of the Novel H1N1 (nH1N1) Pandemic Vaccines Against Influenza/A Positive, Febrile Medically Attended Acute Respiratory Illness (fMAARI) During the 2009 Fall Pandemic in Central Texas. Thirteenth Annual Conference on Vaccine Research. Bethesda, MD.